Two female scientists in the US and UK granted $400k for promising lung cancer research

Funding supports search for new treatments for the deadliest form of cancer

Wednesday, November 16, 2016 — More people die from lung cancer every year than any other cancers, and researchers are hard-pressed to find funding for studies that could improve treatments. As November is Lung Cancer Awareness Month, there is hopeful news.
 

More people die from lung cancer every year than any other cancers, and researchers are hard-pressed to find funding for studies that could improve treatments. As November is Lung Cancer Awareness Month, there is hopeful news.

The Lung Cancer Foundation of America (LCFA) and International Association for the Study of Lung Cancer (IASLC) have partnered to fund the Lori Monroe Scholarship for Lung Cancer Research. These $200,000 grants support promising new research led by two female scientists chosen from among 33 worldwide applicants.

  • Carla Martins, PhD with the University of Cambridge in England, will use the funding to study how exploiting the metabolic heterogeneity of mutant KRAS lung tumors can be used to optimize therapy.

  • Kellie Smith, PhD with Johns Hopkins University School of Medicine in Baltimore will focus on neoantigen targeting in patients with early stage non-small-cell lung carcinoma (NSCLC).

“The IASLC is proud to join LCFA in providing these grants to two very promising young investigators. These important research projects will hopefully lead to encouraging results benefiting many lung cancer patients,” said Dr. Fred R. Hirsch, MD, PhD, CEO of IASLC.

“The LCFA/IASLC Lori Monroe Scholarship for Lung Cancer Research is the kind of private donor funding that is the lifeline for pioneering researchers like Smith and Martins to conduct their important work to help give lung cancer patients improved treatment options,” said Kim Norris, LCFA President and Co-Founder.

To date, LCFA and IASLC have partnered to fund more than $1 million in research grants.

About IASLC

The International Association for the Study of Lung Cancer (IASLC) is the only global organization specifically dedicated to the study of lung cancer. Founded in 1974, the association's membership includes nearly 6,000 lung cancer specialists in 80 countries.

Kellie Smith, PhD with Johns Hopkins University School of Medicine in Baltimore, will focus on neoantigen targeting in patients with early stage non-small-cell lung carcinoma (NSCLC).
Carla Martins, PhD with the University of Cambridge in England, will use the funding to study how exploiting the metabolic heterogeneity of mutant KRAS lung tumors can be used to optimize therapy.